In this week’s Medical Discovery News with UTMB’s David Niesel and Norbert Herzog: Cat allergy sufferers may soon have a new option. A vaccine has been developed by an Oxford-based company called Cicassia that consists of seven peptides, short pieces of the Fel d1 protein. These peptides will appease the cellular part of the immune response while not activating the part that leads to allergic reactions. The ToleroMune vaccine successfully passed both Phase 1 and Phase 2 clinical trials and is in a Phase 3 clinical trial. The vaccine was shown to significantly reduce nose- and eye-related symptoms in response to cat dander.